Seminars in Oncology
Volume 31, Issue 2 , Pages 249-263 , April 2004

Genitourinary cancer in the elderly

  • Derek Raghavan

      Affiliations

    • Division of Oncology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA
    • Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA
    • Corresponding Author InformationAddress reprint requests to Derek Raghavan, MD, Cleveland Clinic Taussig Cancer Center, 9500 Euclid Ave, Cleveland, OH, USA
    • ,
  • Eila Skinner

      Affiliations

    • Department of Urology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA

References 

  1. Jemal A, Murray T, Samuels A, et al.  Cancer statistics 2003. CA Cancer J Clin. 2003;53:5–26
  2. Leventhal EA. The dilemma of cancer in the elderly. In:  Vaeth JM,  Meyer J editor. Cancer and the Elderly. Basel, Switzerland: Karger; 1986;p. 1–13
  3. Bender AD. The effects of increasing age on the distribution of peripheral blood flow in man. J Am Geriatr Soc. 1965;13:192–198
  4. Brandstellar RD, Kazemi H. Aging and the respiratory system. Med Clin North Am. 1983;67:419–431
  5. McLachlan MSF. The ageing kidney. Lancet. 1976;2:143–146
  6. Hartstock RJ, Smith EB, Petty ES. Normal variations with aging on the amount of hematopoietic tissue in bone marrow from the anterior iliac crest. Am J Clin Pathol. 1965;43:326–331
  7. Timiras ML, Brownstein H. Prevalence of anemia and correlation of hemoglobin with age in a geriatric screening clinic population. J Am Geriat Soc. 1987;35:639–643
  8. Lipschitz DG, Udupa KB. Age and the hematopoietic system. J Am Geriatr Soc. 1986;34:448–454
  9. Zauber NP, Zauber AG. Hematologic data of healthy very old people. JAMA. 1987;257:2181–2184
  10. Bender BS, Nagel JE, Adler WH, et al.  Absolute peripheral blood lymphocyte count and subsequent mortality of elderly men. J Am Geriatr Soc. 1986;34:649–654
  11. Anisimov VN. In: Carcinogenesis and Aging. vol 1:Boca Raton, FL: CRC Press; 1987;p. 1–47
  12. Raghavan D, Weiner J, Lipson L. Cancer in the elderly (Principles of treatment). In:  Souhami R,  Tannock I,  Hohenberger P, et al. editor. Oxford Textbook of Oncology. (ed 2). New York, NY: Oxford University Press; 2002;p. 863–874
  13. Mor V, Masterson-Allan S, Goldberg RJ, et al.  Relationship between age at diagnosis and treatment received by cancer patients. J Am Geriatr Soc. 1985;33:585–589
  14. Goodwin JS, Samet JM, Key CR, et al.  Stage at diagnosis of cancer varies with the age of the patient. J Am Geriatr Soc. 1986;34:20–26
  15. Blandy JP, England HR, Evans SJW, et al.  T3 bladder cancer (The case for salvage cystectomy). Br J Urol. 1980;52:506–510
  16. Holmes FF. Clinical evidence for a change in tumor aggressiveness with age. Semin Oncol. 1989;16:34–40
  17. Skinner E, Raghavan D, Kim S, et al.  Management of bladder cancer in the elderly. In:  Raghavan D,  Scher HI,  Leibel SA editor. Principles and Practice of Genitourinary Oncology. Philadelphia, PA: Lippincott-Raven; 1997;p. 307–313
  18. Stein JP, Lieskovsky G, Cote R, et al.  Radical cystectomy in the treatment of invasive bladder cancer (Long-term results in 1,054 patients). J Clin Oncol. 2001;19:666–675
  19. Cook AGB, Watson FR. A comparison by age of death rates due to prostate cancer alone. J Urol. 1968;100:669–671
  20. Smedley HM, Sinnett M, Freedman LS, et al.  Age and survival in prostatic carcinoma. Br J Urol. 1983;55:529–533
  21. Adami H-O, Norlen BJ, Malker B, et al.  Long-term survival in prostatic carcinoma, with special reference to age as a prognostic factor. A nation-wide study. Scand J Urol Nephrol. 1986;20:107–112
  22. Borek D, Butcher D, Hassanein K, et al.  Relationship of age to histologic grade in prostate cancer. Prostate. 1990;16:305–311
  23. Raghavan D, Shipley WU, Richie JP, et al.  Biology and management of bladder cancer. N Engl J Med. 1990;322:1129–1138
  24. Lynch CF, Cohen MB. Urinary system. Cancer. 1995;75(suppl):316–320
  25. Pow-Sang J, Friedland J, Einstein AB. Transitional cell carcinoma of the bladder. In:  Balducci L,  Lyman GH,  Ershler WB editor. Comprehensive Geriatric Oncology. Amsterdam, The Netherlands: Harwood; 1998;p. 697–702
  26. Figueroa AJ, Stein JP, Dickinson M, et al.  Radical cystectomy for elderly patients with bladder carcinoma (An updated experience with 404 patients). Cancer. 1998;83:141–147
  27. Chang SS, Alberts G, Cookson MS, et al.  Radical cystectomy is safe in elderly patients at high risk. J Urol. 2001;166:938–941
  28. Leibovitch I, Avigad I, Ben-Chaim J, et al.  Is it justified to avoid radical cystoprostatectomy in elderly patients with invasive transitional cell carcinoma of the bladder?. Cancer. 1993;71:3098–3101
  29. Soulie M, Straub M, Game X, et al.  A multicenter study of the morbidity of radical cystectomy in select elderly patients with bladder cancer. J Urol. 2002;167:2435–2438
  30. Stroumbakis N, Herr HW, Cookson MS, et al.  Radical cystectomy in the octogenarian. J Urol. 1997;158:2113–2117
  31. Pollack A, Zagars GK, Swanson DA. Muscle-invasive bladder cancer treated with external beam radiotherapy (Prognostic factors). Int J Radiat Oncol Biol Phys. 1994;30:267–277
  32. Duncan W, Quilty PM. the results of a series of 963 patients with transitional cell carcinoma of the bladder primarily treated by radical megavoltage X-ray therapy. Radiother Oncol. 1986;7:299–304
  33. Gospodarowicz MK, Hawkins NV, Rawlings GA, et al.  Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder (Failure analysis). J Urol. 1989;142:1448–1453
  34. Smaaland R, Akslen L, Tonder B, et al.  Radical radiation treatment of invasive and locally advanced bladder carcinoma in elderly patients. Br J Urol. 1991;67:61–67
  35. Raghavan D, Grundy R, Greenaway TM, et al.  Preemptive (neo-adjuvant) chemotherapy prior to radical radiotherapy for fit septuagenarians with bladder cancer (Age itself is not a contra-indication). Br J Urol. 1988;62:154–158
  36. Coppin C, Gospodarowicz M, James K, et al.  Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. J Clin Oncol. 1996;14:2901–2907
  37. Shipley WU, Kaufman DS, Tester WJ, et al.  Overview of bladder cancer trials in the Radiation Therapy Oncology Group. Cancer. 2003;97(suppl):2115–2119
  38. Loehrer PJ, Einhorn LH, Elson PJ, et al.  A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma (A cooperative group study). J Clin Oncol. 1992;10:1066–1072
  39. Von der Maase H, Hansen SW, Roberts JT, et al.  Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer (Results of a large, randomized, multinational, multicenter phase III study). J Clin Oncol. 2000;17:3068–3077
  40. Crawford ED, Wood DP, Petrylak DP, et al.  Southwest Oncology Group studies in bladder cancer. Cancer. 2003;97(suppl):2099–2108
  41. Krongrad A, Lai H, Lamm SH, et al.  Mortality in prostate cancer. J Urol. 1996;156:1084–1091
  42. Coley CM, Barry MJ, Mulley AG. Clinical guideline: Part III: Screening for prostate cancer. Ann Intern Med. 1991;126:480–484
  43. Smith RA, Mettlin CJ, Davis KJ, et al.  American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin. 2000;50:34–40
  44. Oesterling JE, Jacobsen SJ, Chute CG, et al.  Serum prostate-specific antigen in a community based population of healthy men (Establishment of age-specific reference ranges). JAMA. 1993;270:860–863
  45. Morgan TO, Jacobsen SJ, McCarthy WF, et al.  Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med. 1996;335:304–309
  46. Chybowski FM, Larson-Keller JJ, Bergstralh EJ, et al.  Predicting radionuclide bone scan findings in patients with newly diagnosed untreated prostate cancer (Prostate specific antigen is superior to all other clinical parameters). J Urol. 1991;145:313–318
  47. Albertson PC, Hanley JA, Harlan LC, et al.  The positive yield of imaging studies in the evaluation of men with newly diagnosed prostate cancer (A population based analysis). J Urol. 2000;163:1138–1143
  48. Albertson PC, Hanley JA, Gleason DF, et al.  Competing risk analysis of men age 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 1998;280:975–980
  49. Aus G, Hugosson J, Norlen L. Long-term survival and mortality in prostate cancer treated with noncurative intent. J Urol. 1995;154:460–465
  50. Krongrad A, Lai H, Lamm SH, Lai S. Mortality in prostate cancer. J Urol. 1996;156:1084–1091
  51. Koppie TM, Grossfeld GD, Miller D, et al.  Patterns of treatment of patients with prostate cancer initially managed with surveillance: Results from The CaPSURE database. Cancer of the Prostate Strategic Urological Research Endeavor. J Urol. 2000;164:81–88
  52. Martin JA, Smith BL, Matthews TJ, et al.  Births and deaths (Preliminary data for 1998). Natl Vital Stat Rep. 1999;47:1–45
  53. Rabbani F, Stapleton AM, Kattan MW, et al.  Factors predicting recovery of erections after radical prostatectomy. J Urol. 2000;164:1929–1934
  54. Bolla M, Gonzalez D, Warde P, et al.  Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337:295–300
  55. Pilepich MV, Caplan R, Byhardt RW, et al.  Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy (Report of Radiation Therapy Oncology Group Protocol 85–31). J Clin Oncol. 1997;15:1013–1021
  56. Byar DP, Corle DK. Hormone therapy for prostate cancer. Results of the Veterans Administration cooperative Urological Research Group studies. NCI Monogr. 1988;7:165–170
  57. Medical Research Council Prostate Cancer Working Party Investigators Group . Immediate versus deferred treatment for advanced prostatic cancer (Initial results of the Medical Research Council Trial). Br J Urol. 1997;79:235–240
  58. Raghavan D. Prostate cancer management under scrutiny (One man’s meta-analysis is another man’s Poisson). J Clin Oncol. 1999;17:3371–3373
  59. Messing EM, Mannola J, Sarosdy M, et al.  Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;341:1781–1788
  60. Beer T, Raghavan D. Chemotherapy for hormone-refractory prostate cancer (Beauty is in the eye of the beholder). Prostate. 2000;45:184–193
  61. Raghavan D, Pearson B, Coorey G, et al.  Management of hormone-resistant prostate cancer (Experience at Royal Prince Alfred Hospital). In:  Johnson DE,  Logothetis CJ,  von Eschenbach AC editor. Systemic Therapy for Genitourinary Cancers. Chicago, IL: Year Book Medical Publishers; 1989;p. 245–250
  62. Tannock IF, Osoba D, Stockler MR, et al.  Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer (A Canadian randomized trial with palliative end points). J Clin Oncol. 1996;14:1756–1764
  63. Kantoff PW, Halabi S, Conaway M, et al.  Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer (Results of the cancer and leukemia group B 9182 study). J Clin Oncol. 1999;17:2506–2513
  64. Chow WH, Devesa SS, Warren JL, et al.  Rising incidence of renal cell cancer in the United States. JAMA. 1999;281:1628–1631
  65. Hock LM, Lynch J, Balaji KC. Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States (An analysis of surveillance, epidemiology and end results program data). J Urol. 2002;167:7–60
  66. Damhuis RAM, Blom JHM. The influence of age on treatment choice and survival in 735 patients with renal carcinoma. Br J Urol. 1995;75:143–147
  67. Samet J, Hunt WC, Key C, et al.  Choice of cancer therapy varies with the age of patients. JAMA. 1986;255:3385–3390
  68. Dunn MD, Portis AJ, Shalhav AL, et al.  Laparoscopic versus open radical nephrectomy (A 9-year experience). J Urol. 2000;164:1153–1159
  69. Hsu THS, Gill IS, Fazeli-Matin S, et al.  Radical nephrectomy and nephroureterectomy in the octogenarian and nonagenarian (Comparison of laparoscopic and open approaches). Urology. 1999;53:1121–1125
  70. Gill IS, Novick AC, Meraney AM, et al.  Laparoscopic renal cryoablation in 32 patients. Urology. 2000;56:748–753
  71. Desai MM, Gill IS. Current status of cryoablation and radiofrequency ablation in the management of renal tumors. Curr Opin Urol. 2002;12:387–393
  72. Ogan K, Jacomides L, Dolmatch BL, et al.  Percutaneous radiofrequency ablation of renal tumors (Technique, limitations, and morbidity). Urology. 2002;60:954–958
  73. Flanigan RC, Salmon SE, Blumenstein BA, et al.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655–1659
  74. Motzer RJ, Bander NH, Nanus DM. Renal cell carcinoma. N Engl J Med. 1996;335:865–875
  75. Rini BI, Vogelzang NJ, Dumas MC, et al.  Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol. 2000;18:2419–2426
  76. Fyfe G, Fisher RI, Rosenberg SA, et al.  Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;15:688–696
  77. Horwich A, Mason M, Hendry W. Testicular tumours. In:  Souhami RL,  Tannock I,  Hohenberger P editor. Oxford Textbook of Oncology. (ed 2). Oxford, UK: Oxford University Press; 2002;p. 2006–2035
  78. Morrison VA. Non-Hodgkin’s lymphoma in the elderly. In:  Grossbard ML editors. American Cancer Society Atlas of Clinical Oncology-Malignant Lymphomas. Toronto, Canada: Decker; 2002;p. 276–288
  79. Monfardini S, Carbone A. Non-Hodgkin’s lymphomas. In:  Balducci L,  Lyman GH,  Ershler WB editor. Comprehensive Geriatric Oncology. Amsterdam, The Netherlands: Harwood; 1998;p. 577–594

PII: S0093-7754(03)00672-9

doi: 10.1053/j.seminoncol.2003.12.034

Seminars in Oncology
Volume 31, Issue 2 , Pages 249-263 , April 2004

Article Tools

* Image Usage & Resolution